Pulmonary hypertension in bronchopulmonary dysplasia

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 100, Issue 3, 2014, Pages 240-246

  Ambalavanan, Namasivayam ^a   Mourani, Peter ^b  

^a University of Alabama at Birmingham   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Infant; Premature; Pulmonary hypertension; Respiratory distress syndrome

Indexed keywords

AMBRISENTAN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CORTICOSTEROID; DIURETIC AGENT; ELECTROLYTE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TREPROSTINIL; OXYGEN;

ANATOMY; ARTICLE; CLINICAL FEATURE; CYANOSIS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTREMELY LOW BIRTH WEIGHT; FLUID THERAPY; HEART CATHETERIZATION; HEART INJURY; HUMAN; HYPEROXIA; HYPOTENSION; HYPOXIA; LIVER TOXICITY; LUNG BLOOD VESSEL; LUNG DYSPLASIA; LUNG EDEMA; LUNG VASCULAR RESISTANCE; LUNG VEIN OBSTRUCTION; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NUTRITION; OXYGEN SATURATION; PATHOLOGY; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; BLOOD; BRONCHOPULMONARY DYSPLASIA; COMPLICATION; HYPERTENSION, PULMONARY; NEWBORN; PATHOPHYSIOLOGY;

BRONCHOPULMONARY DYSPLASIA; HUMANS; HYPERTENSION, PULMONARY; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; NATRIURETIC PEPTIDE, BRAIN; OXYGEN;

EID: 84896494908     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23241     Document Type: Article

References (44)

1. Abman SH, Wolfe RR, Accurso FJ, et al. 1985. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 75:80-84.
2. Ali Z, Schmidt P, Dodd J, Jeppesen DL. 2013. Predictors of bronchopulmonary dysplasia and pulmonary hypertension in newborn children. Dan Med J 60:A4688.
3. Ambalavanan N, Walsh M, Bobashev G, et al. 2011. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. Pediatrics 127:e106-e116.
4. An HS, Bae EJ, Kim GB, et al. 2010. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 40:131-136.
5. Barst RJ, Ivy DD, Gaitan G, et al. 2012. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125:324-334.
6. Berman W Jr, Yabek SM, Dillon T, et al. 1982. Evaluation of infants with bronchopulmonary dysplasia using cardiac catheterization. Pediatrics 70:708-712.
7. Bhandari V, Bizzarro MJ, Shetty A, et al. 2006. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 117:1901-1906.
8. Bhat R, Salas AA, Foster C, et al. 2012. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 129:e682-689.
9. Bhatt AJ, Pryhuber GS, Huyck H, et al. 2001. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164(Pt 1):1971-1980.
10. Bonikos DS, Bensch KG, Northway WH Jr, Edwards DK. 1976. Bronchopulmonary dysplasia: the pulmonary pathologic sequel of necrotizing bronchiolitis and pulmonary fibrosis. Hum Pathol 7:643-666.
11. Check J, Gotteiner N, Liu X, et al. 2013. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol 33:553-557.
12. Coalson JJ. 2003. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 8:73-81.
13. Coalson JJ. 2006. Pathology of bronchopulmonary dysplasia. Semin Perinatol 30:179-184.
14. Czernik C, Rhode S, Metze B, et al. 2012. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One 7:e38352.
15. Del Cerro MJ, Sabate Rotes A, Carton A, et al. 2014. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr Pulmonol 49:49-59.
16. Eronen M, Pohjavuori M, Andersson S, et al. 1997. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 18:3-7.
17. Filippone M, Carraro S, Baraldi E. 2010. From BPD to COPD? The hypothesis is intriguing but we lack lung pathology data in humans. Eur Respir J 35:1419-1420; author reply 1420.
18. Gurakan B, Kayiran P, Ozturk N, et al. 2011. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. Pediatr Pulmonol 46:617-620.
19. Hartling L, Liang Y, Lacaze-Masmonteil T. 2012. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 97:F8-F17.
20. Hislop AA, Moledina S, Foster H, et al. 2011. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 38:70-77.
21. Hwang SK, O YC, Kim NS, et al. 2009. Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J 39:343-345.
22. Ivy DD, Rosenzweig EB, Lemarie JC, et al. 2010. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 106:1332-1338.
23. Khemani E, McElhinney DB, Rhein L, et al. 2007. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120:1260-1269.
24. Kim DH, Kim HS, Choi CW, et al. 2012. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology 101:40-46.
25. Kim GB. 2010. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 53:688-693.
26. Kim JS, Shim EJ. 2012. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J 42:192-196.
27. Konig K, Barfield CP, Guy KJ, et al. 2014. The effect of sildenafil on evolving bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled pilot study. J Matern Fetal Neonatal Med 27:439-444.
28. Krishnan U, Krishnan S, Gewitz M. 2008. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 29:1082-1086.
29. Mohamed WA, Ismail M. 2012. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 32:608-613.
30. Mourani PM, Ivy DD, Gao D, Abman SH. 2004. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 170:1006-1013.
31. Mourani PM, Sontag MK, Ivy DD, Abman SH. 2009. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 154:379-384, 384 e371-e372.
32. Mourani PM, Sontag MK, Younoszai A, et al. 2008. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 121:317-325.
33. Northway WH Jr, Rosan RC, Porter DY. 1967. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276:357-368.
34. Nyp M, Sandritter T, Poppinga N, et al. 2012. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 32:64-69.
35. Piastra M, De Luca D, De Carolis MP, et al. 2012. Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series. Pediatr Pulmonol 47:757-762.
36. Rosenzweig EB, Ivy DD, Widlitz A, et al. 2005. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46:697-704.
37. Rugolotto S, Errico G, Beghini R, et al. 2006. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Minerva Pediatr 58:491-494.
38. Sanjeev S, Pettersen M, Lua J, et al. 2005. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 25:709-713.
39. Shi W, Warburton D. 2010. Is COPD in adulthood really so far removed from early development? Eur Respir J 35:12-13.
40. Skinner JR, Stuart AG, O'Sullivan J, et al. 1993. Right heart pressure determination by Doppler in infants with tricuspid regurgitation. Arch Dis Child 69:216-220.
41. Slaughter JL, Pakrashi T, Jones DE, et al. 2011. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 31:635-640.
42. Stuart BD, Sekar P, Coulson JD, et al. 2013. Health-care utilization and respiratory morbidities in preterm infants with pulmonary hypertension. J Perinatol 33:543-547.
43. Wardle AJ, Wardle R, Luyt K, Tulloh R. 2013. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Arch Dis Child 98:613-617.
44. Zaidi AN, Dettorre MD, Ceneviva GD, Thomas NJ. 2005. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Pediatr Pulmonol 40:265-269.